{"prompt": "['Interferon beta-la', 'MESTRE-MS Study', 'EMR200136_597', '9.7.4', 'Sequence of Analyses', '33', '9.8', 'Quality Control', '34', '9.8.1', 'Monitoring', '34', '9.8.2', 'Archiving', '34', '9.8.3', 'Quality Assurance and Audit', '34', '9.9', 'Limitations of the Research Methods', '34', '9.10', 'Other Aspects', '35', '10', 'Protection of Human Subjects', '35', '10.1', 'Independent Ethics Committee or Institutional Review Board', '35', '10.2', 'Subject Information and Informed Consent', '35', '10.3', 'Subject Identification and Privacy', '36', '10.4', 'Health Authorities', '37', '11', 'Management and Reporting of Adverse Events', '37', '11.1', 'Adverse Events', '37', '11.2', 'Severity of Adverse Events', '38', '11.3', 'Causality Assessment', '38', '11.4', 'Recording of Adverse Events in the Case Report Form', '39', '11.5', 'Safety Reporting to the Study Sponsor', '39', '11.6', 'Regulatory Reporting to the Health Authorities', '42', '12', 'Plans for Disseminating and Communicating Study Results', '42', '12.1', 'Study Report(s)', '42', '12.2', 'Publication', '42', '13', 'References', '44', '14', 'Appendices', '47', '15', 'Annexes', '56', '15.1', 'Signature pages and responsible persons for the study', '57', 'Signature Page - Protocol Lead', '58', 'Signature Page - -Coordinating Investigator', '59', 'Signature Page - Principal Investigator', '60', 'CONFIDENTIAL', '4/60', 'INFORMATION', 'M']['Interferon beta-la', 'MESTRE-MS Study', 'EMR200136_597', 'List of Tables', 'Table 1', 'Schedule of Assessments and Evaluations', '28', 'List of Figures', 'Figure 1', 'Study Overview', '23', 'CONFIDENTIAL', '5/60', 'INFORMATION', 'V']['Interferon beta-la', 'MESTRE-MS Study', 'EMR200136_597', '2', 'List of Abbreviations', 'AE', 'Adverse Event', 'AR', 'Adverse Reaction', 'ARR', 'Annualized Relapse Rate', 'CI', 'Confidence Interval', 'CRF', 'Case Report Form', 'CRO', 'Contract Research Organization', 'DMD', 'Disease Modifying Drug', 'eCRF', 'Electronic Case Report Form', 'EDSS', 'Expanded Disability Status Scale', 'HCP', 'Health Care Professional', 'ICF', 'Informed Consent Form', 'IEC', 'Independent Ethics Committee', 'IFNB', 'Interferon beta', 'IRB', 'Institutional Review Board', 'MAH', 'Marketing Authorisation Holder', 'MS', 'Multiple Sclerosis', 'MusiQoL', 'Multiple Sclerosis International Quality of Life Questionnaire', 'Q1', 'First Quartile', 'Q3', 'Third Quartile', 'RRMS', 'Relapsing Remitting Multiple Sclerosis', 'SAE', 'Serious Adverse Event', 'SAP', 'Statistical Analysis Plan', 'SD', 'Standard Deviation', 'SmPC', 'Summary of Product Characteristics', 'TSQM V II', 'Treatment Satisfaction Questionnaire for Medication Version II', 'CONFIDENTIAL', '6/60', 'INFORMATION', 'M']\n\n###\n\n", "completion": "END"}